Diabetic Macular Edema Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2024" report provides comprehensive insights about 60+ Diabetic Macular Edema companies and 65+ Diabetic Macular Edema pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Diabetic Macular Edema Pipeline Report
• Over 60+ Diabetic Macular Edema companies are evaluating 65+ Diabetic Macular Edema pipeline therapies in various stages of development, and their anticipated acceptance in the Diabetic Macular Edema market would significantly increase market revenue.
• The leading Diabetic Macular Edema companies working in the market include Mylan Pharmaceuticals, Kodiak sciences, Celltrion, Exonate, Opthea, Asclepi X Therapeutics, Allgenesis Biotherapeutics, Ascentage Pharma, Rezolute, Ocuphire Pharma, Oxurion, MingSight Pharmaceuticals, Adverum Biotechnologies, and others.
• Promising Diabetic Macular Edema Pipeline Therapies in the various stages of development include MYL-1701P, Eylea, Dexamethasone ophthalmic suspension (OCS-01), REGN910-3, Intravitreal Aflibercept Injection (IAI), and others.
• April 2024: AbbVie- A Multi-country, Post Marketing Observational Study of DME Patients With Suboptimal Response to Anti-VEGF Who Are Initiated With Dexamethasone Intravitreal Implant (DEX-I).
• April 2024: Bayer announced a study of Phase 4 clinical trials for Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321). The main purpose of this study is to collect more data to learn how safe intravitreal aflibercept is in Indian people with DME. To see how safe intravitreal aflibercept is, the researchers will collect the information/data on the medical problems the participants may have during the study, and which may or may not be related to the study treatment. These medical problems are also known as "adverse events" (AEs). AEs will be categorized according to relatedness, seriousness, discontinuation of therapy, action taken and outcome.

Request a sample and discover the recent breakthroughs happening in the Diabetic Macular Edema Pipeline landscape @ Diabetic Macular Edema Pipeline Outlook Report- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Diabetic Macular Edema pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Diabetic Macular Edema NDA approvals (if any), and product development activities comprising the technology, Diabetic Macular Edema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Diabetic Macular Edema Overview
Diabetic Macular Edema (DME) is an eye condition which can occur in people living with diabetes - both type 1 and type 2. Consistently high blood sugar due to poor glucose control over time can damage small blood vessels in the body, including the eye.

Find out more about Diabetic Macular Edema Therapeutics Assessment @ Diabetic Macular Edema Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Macular Edema Emerging Therapies Profile

• MYL-1701P: Mylan Pharmaceuticals
MYL-1701P (also referred to as M710, as part of a partnership with Momenta Pharmaceuticals) is perhaps the aflibercept biosimilar that is furthest along in the development process. It is currently the subject of a 324-patient phase III trial. Mylan is to handle development and commercialization.

• KSI-301: Kodiak sciences
KSI-301 is a novel anti-VEGF biologic built on a propriety antibody biopolymer conjugate (ABC) platform KSI-301 is designed to have extended ocular half-life, higher potency, and improved ocular tissue bioavailability. KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of VEGF for up to 6 months. The unique properties of KSI- 301 aim to provide patients with long-term control of their DME with improved vision outcomes while reducing the burden of frequent anti-VEGF injections. In addition, KSI-301 is designed to halt and reverse DR progression with long-term efficacy that can reduce the risk of vision-threatening complications from DR. The Phase III GLEAM and GLIMMER studies are global, multi-center, randomized studies designed to evaluate the efficacy, durability and safety of KSI-301 in patients with treatment-naïve diabetic macular edema (DME).

• CT-P42: Celltrion
CT-P42, an aflibercept biosimilar referencing Regeneron's Eylea. The trial will enroll 300 patients with diabetic macular edema, and aims to compare CT-P42's efficacy, safety, pharmacokinetics, and immunogenicity against Eylea.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of diabetic macular edema (DME)

Diabetic Macular Edema Therapeutics Assessment
There are approx. 60+ key Diabetic Macular Edema companies which are developing the Diabetic Macular Edema therapies. The Diabetic Macular Edema companies which have their Diabetic macular edema drug candidates in the most advanced stage, i.e. Phase III include, Mylan Pharmaceuticals.

DelveInsight's Diabetic Macular Edema pipeline report covers around 65+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Diabetic macular edema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Diabetic Macular Edema Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Diabetic Macular Edema Pipeline Therapies @ Diabetic Macular Edema Clinical Trials Assessment-

Scope of the Diabetic Macular Edema Pipeline Report
• Coverage- Global
• Diabetic Macular Edema Companies- Mylan Pharmaceuticals, Kodiak sciences, Celltrion, Exonate, Opthea, Asclepi X Therapeutics, Allgenesis Biotherapeutics, Ascentage Pharma, Rezolute, Ocuphire Pharma, Oxurion, MingSight Pharmaceuticals, Adverum Biotechnologies, and others.
• Diabetic Macular Edema Pipeline Therapies- MYL-1701P, Eylea, Dexamethasone ophthalmic suspension (OCS-01), REGN910-3, Intravitreal Aflibercept Injection (IAI), and others.
• Diabetic Macular Edema Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

Dive deep into rich insights for drugs for Diabetic Macular Edema Pipeline Companies and Therapies, click here @ Diabetic Macular Edema Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Diabetic macular edema: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. MYL-1701P: Mylan Pharmaceuticals
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Diabetic macular edema Key Companies
17. Diabetic macular edema Key Products
18. Diabetic macular edema- Unmet Needs
19. Diabetic macular edema- Market Drivers and Barriers
20. Diabetic macular edema- Future Perspectives and Conclusion
21. Diabetic macular edema Analyst Views
22. Diabetic macular edema Key Companies
23. Appendix

Got Queries? Find out the related information on Diabetic Macular Edema Mergers and acquisitions, Diabetic Macular Edema Licensing Activities @ Diabetic Macular Edema Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.